The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...

Robert F. Kennedy Jr.’s selection Thursday as President-elect Donald Trump’s Health and Human Services secretary nominee sent shockwaves through Washington.

The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease ...

Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Biogen (BIIB – Research Report) and keeping the price target at ...

Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...

The agency's new guidelines require drugmakers to provide viewers with a clearer picture of medications' risks and side effects. Congress also is looking at giving the FDA authority to regulate drug ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced ...

If the European Commission decides to grant sales of the medicine, it will be the first Alzheimer's medicine available in the ...

The article provides an overview of recent developments in the healthcare sector, including Novo Nordisk's phase-out of ...

Discover how the National Diabetes Prevention Program can change your life! With guidance from expert facilitators and ...